Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 in Advanced, Refractory Hematologic Malignancies
NCT02352558Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of napabucasin in multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML) and 3 more (9 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Dose-Limiting Toxicities at 4 weeks. Started May 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
multiple myeloma (MM)lymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02352558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352558.